You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

α-synuclein Imaging: A Critical Need for Parkinson's Disease Research

Article type: Research Article

Authors: Eberling, Jamie L. | Dave, Kuldip D. | Frasier, Mark A.

Affiliations: The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA

Note: [] Correspondence to: Jamie L. Eberling, Michael J. Fox Foundation, 498 Seventh Avenue, 18th, Floor, New York, NY 10018, USA. Tel.: +1 212 509 0995; Fax: +1 212 509 2390; Email: [email protected]

Keywords: α-synuclein, positron emission tomography, radiopharmaceutical, biomarker, β-amyloid, tau

DOI: 10.3233/JPD-130247

Journal: Journal of Parkinson's Disease, vol. 3, no. 4, pp. 565-567, 2013

Published: 2013
Get PDF open access

Abstract

The development of an α-synuclein imaging agent could be transformative for Parkinson's disease research and drug development. The ability to image α-synuclein in the brain would enable tracking of the degree and location of pathology over time and monitoring of therapies aimed at reducing α-synuclein levels. The Michael J. Fox Foundation has assembled a consortium of researchers to develop an α-synuclein radiotracer for use in positron emission tomography (PET) imaging studies. While this poses a number of challenges they should not be insurmountable and lessons learned from the development of tau radiotracers should provide valuable insights.

Show more